Expression of PKCα, PKCε, and P-gp in epithelial ovarian carcinoma and the clinical significance

Aim: To inspect the expression of two protein kinase PKC isozyme hypotype PKCα and PKCε in the epithelial ovarian carcinoma tissue, and investigate their relation with multi-drug resistance with P-glycoprotein (P-gp) medium. Materials and Methods: Adopted immunohistochemistry SP method to determine expression of PKCα, PKCε, and P-gp in 64 cases of epithelial ovarian carcinoma, 18 cases of epithelial borderline ovarian carcinoma, 15 cases of epithelial ovarian benign tumor, and 15 cases of normal ovarian tissue. Results: The expression of PKCα, PKCε, and P-gp in the epithelial ovarian carcinoma is obviously higher than expression in the normal, benign. and borderline epithelial ovarian carcinoma; the expression of PKCα, PKCε, and P-gp in the recurrent carcinoma tissue is obviously higher than that in the person with initial treatment; the expression of above-mentioned three indicators in epithelial ovarian carcinoma is unrelated with the pathological type, pathological grade, and clinical stage during initial treatment of the carcinoma; there is a close relation among PKCα, PKCε, and P-gp in epithelial ovarian carcinoma (p < 0.01). It is indicated through research that PKCα, PKCε, and P-gp is related with the survival time and poor prognosis of the patient of epithelial ovarian carcinoma, i.e., the positive expressionrate of PKCα, PKCε, and P-gp of the person with recurrent carcinoma is higher than that of the person without recurrent carcinoma (p < 0.05). However, the survival rate of the patients with positive expression of three indicators is remarkably lower than those with negative expression (p < 0.05). Conclusion: There is a consistency between expression of PKCα, PKCε, and P-gp in the epithelial ovarian carcinoma, which indicates that the expression of both plays an important role in generation of drug resistance in chemotherapy of ovarian carcinoma with P-gp medium. Joint detection of three indicators has an active guiding role in judgment of the therapeutic effect of clinical chemotherapy and prognosis estimation of the patient.

Epithelial ovarian carcinoma; PKCα;PKCε; P-gp; Immunohistochemistry; Multi-drug resistance.

[1] Shen K., Lang J.:“Issues and challenges of gynecologic oncology”. Beijing: People’s Health Publishing House, 2002, 112.

[2] Marsh K.L.,Varley J.M.: “Frequeut alterations of cell cycle regulaors in early-stage breast lesions as detected by immunohistochemistry”. Br. J. Cancer, 1998, 77, 1460.

[3] Aouali N., Eddabra L., Macadré J., Morjani H.: “Immunosuppressors and reversion of multidrug-resistance”. Crit. Rev. Oncol. Hematol., 2005, 56, 61.

[4] Lu D., Wang Z.:“Multi-drug Resistance Gene Protein Expression in the Ovarian Carcinoma Tissue and the Clinical Value”. Cancer Research on Prevention and Treatment, 2004, 5, 512.

[5] Prevostel C., Alvaro V., de Boisvilliers F., Martin A., Jaffiol C., Joubert D.:“The natural protein kinase C alpha mutant is present in human thyroid neoplasms”. Oncogene, 1995, 11, 669.

[6] Kitazaki T., Oka M., Nakamura Y., Tsurutani J., Doi S.,Yasunaga M., et al.: “Gefitinib,an EGFR tyrosine kinase inhibitor,directly inhibits the function of P-glycoprotein in mulidrug resistant cancer cells”. Lung Cancer, 2005, 49, 337.

[7] Zhan M., Yu D.,Liu J.: “Transcriptional repression of protein kinase calpha via spl by wild type p53 is involved in inhibition of multidrug resistance l P-glycoprotein phosphorylation”. Biol. Chem., 2005, 280, 225.

[8] Lee S.K., Shehzad A., Jung J.C., Sonn J.K., Lee J.T., Park J.W., Lee Y.S.: “Protein kinase Cα protects against multidrug resistance in human colon cancer cells”. Mol. Cells, 2012, 34, 61.

[9] Beltran P.J., Fan D., Fidler I.J., O`Brian C.A.: “Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation”. Biochem. Pharmacol., 1997, 53, 245.

[10] Gill P.K., Gescher A., Gant T.W.: “Regulation of MDRl promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta”. Eur. J. Biochem., 2001, 268, 4151.

[11] Sun L.R., Zhong J.L., Cui S.X., Li X., Ward S.G., Shi Y.Q., et al.:“Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells”. Pharmacol. Rep., 2010, 62, 333.

[12] Wang W., Yang X.,Wu S.:“Influence of different protein kinase C isozyme hypotypes on the drug resistance of ovarian carcinoma cells”. Progress in Obstetrics and Gynecology, 2003, 12, 351.

[13] Beck J.F., Bohnet B., Brügger D., Dietl J., Scheper R.J., Bader P., et al.: “Expression analysis of protein kinase C isozymes and multidrug resistance associated genes in ovarian cancer cells”. Anticancer Res., 1998, 18, 701.

[14] Flescher E. Rotem R.: “Protein kinase C epsilon mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells”. Cell. Signal., 2002, 14, 37.

[15] Shtili A.A.: “Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells”. Curr. Drug Targets, 2001, 2, 57.

[16] Wang F., Han R.: “Development of research for drug - resistance mechanism of taxol”. Ai Zheng, 2002, 21, 439.